Amplia requests ASX trading halt ahead of key clinical trial data

Amplia Therapeutics ( (AU:ATX) ) just unveiled an announcement.

Amplia Therapeutics has requested and been granted a trading halt on its ASX-listed securities, effective 19 March 2026, as it prepares to release clinical trial results derived from a central reading of new data. The halt, which is expected to remain in place until either the announcement is released or normal trading resumes on 23 March 2026, is intended to give the company time to assess the data and inform the market in an orderly manner.

The move signals that potentially market-sensitive clinical findings are imminent, with implications for Amplia’s development pipeline of FAK inhibitors and its valuation outlook. Investors and industry stakeholders will closely watch the forthcoming announcement, as the trial outcomes could influence Amplia’s strategic direction in oncology and fibrosis and may affect sentiment toward its position among emerging Australian biotech developers.

The most recent analyst rating on (AU:ATX) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

More about Amplia Therapeutics

Amplia Therapeutics Limited is an Australian pharmaceutical company developing a pipeline of focal adhesion kinase (FAK) inhibitors targeting cancer and fibrosis. The company focuses particularly on fibrotic cancers such as pancreatic and ovarian cancer, and is also exploring FAK’s role in chronic diseases including idiopathic pulmonary fibrosis, positioning Amplia within niche but growing oncology and fibrosis markets.

Average Trading Volume: 636,268

Technical Sentiment Signal: Sell

Current Market Cap: A$57.72M

For an in-depth examination of ATX stock, go to TipRanks’ Overview page.